Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 3/20 | 0.41 |
| ▸ | PLK4 | O00444 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 8/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042402 | 0.81 | PAK1 (0.46) | PAK4IGF1RNTRK1 | |
| SCHEMBL13221083 | 0.81 | GSK3B (0.53) | PLK4AURKAJAK2AURKBGSK3B | |
| SCHEMBL5095246 | 0.80 | ITK (0.44) | MEN1HTTKMT2AHSD17B10AURKA | |
| SCHEMBL3031923 | 0.79 | IGF1R (0.45) | PAK4PLK4AURKAJAK2AURKB | |
| SCHEMBL13220902 | 0.79 | IGF1R (0.45) | PAK4PLK4AURKAJAK2AURKB | |
| SCHEMBL3040351 | 0.78 | MEN1 (0.46) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL3044547 | 0.78 | SYK (0.33) | PLK4AURKAJAK2AURKBGSK3B | |
| SCHEMBL3042183 | 0.78 | AURKA (0.50) | PAK4PLK4AURKAJAK2AURKB | |
| SCHEMBL13221166 | 0.78 | PLK4 (0.42) | MEN1HTTKMT2AHSD17B10PAK4 | |
| SCHEMBL13220896 | 0.77 | SYK (0.42) | PLK4AURKAJAK2AURKBGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| EP-1812439-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20060084650-A1 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084650-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | MEN1 1423/4885HTT 4414/4885KMT2A 1184/4885 |
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | MEN1 1423/4885HTT 4414/4885KMT2A 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.